CANN:CNSX-Heritage Cannabis Holdings Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 0.05

Change

0.00 (0.00)%

Market Cap

CAD 0.04B

Volume

1.06M

Avg Analyst Target

N/A

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Heritage Cannabis Holdings Corp (CANN) Stock Analysis:
Based on the Heritage Cannabis Holdings Corp stock forecasts from 0 analysts, the average analyst target price for Heritage Cannabis Holdings Corp is not available over the next 12 months. Heritage Cannabis Holdings Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Heritage Cannabis Holdings Corp is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Heritage Cannabis Holdings Corp’s stock price was CAD 0.05. Heritage Cannabis Holdings Corp’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -59.09% over the last year.

About

Heritage Cannabis Holdings Corp., through its subsidiaries, operates as a cannabinoid company that focuses on the production and sale of medical and recreational hemp-based and cannabis-based products and services in Canada and the United States. It offers extraction services; an ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

N/A

CAD5.71B N/A 19.93
GTII:CA Green Thumb Industries Inc

N/A

CAD3.93B 32.53 10.75
TRUL:CA Trulieve Cannabis Corp

N/A

CAD3.54B 121.35 16.20
VRNO:CA Verano Holdings Corp

N/A

CAD2.65B 13.46 13.78
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
CL:CA Cresco Labs Inc

N/A

CAD1.47B N/A 20.98
TER:CA TerrAscend Corp

N/A

CAD1.46B 360.77 20.82
CCHW:CA Columbia Care Inc

N/A

CAD0.96B N/A 127.53
FFNT:CA 4Front Ventures Corp

N/A

CAD0.57B N/A N/A
LHS:CA Liberty Health Sciences Inc

N/A

CAD0.51B 147.00 13.82

ETFs Containing CANN:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.77% 68% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.77% 68% D+ 60% D-
Trailing 12 Months  
Capital Gain -59.09% 67% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.09% 67% D+ 51% F
Trailing 5 Years  
Capital Gain -25.00% 80% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.00% 80% B- 60% D-
Average Annual (5 Year Horizon)  
Capital Gain -22.29% 18% F 11% F
Dividend Return N/A 27% F 2% F
Total Return -22.29% 18% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 38.01% 38% F 48% F
Risk Adjusted Return -58.63% 18% F 14% F
Market Capitalization 0.04B 73% C 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.37 87% B+ 91% A-
Price / Cash Flow Ratio -1.75 44% F 27% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -93.05% 54% F 48% F
Return on Invested Capital -21.64% 60% D- 67% D+
Return on Assets -12.71% 60% D- 76% C
Debt to Equity Ratio 19.87% 39% F 28% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.01 100% A+ 97% A+
Short Percent N/A N/A N/A N/A N/A
Beta -0.05 85% B 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector